# GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

> **NCT01480583** · PHASE2 · COMPLETED · sponsor: **Angiochem Inc** · enrollment: 85 (actual)

## Conditions studied

- Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** GRN1005
- **DRUG:** Trastuzumab
- **DRUG:** 18F-FLT

## Key facts

- **NCT ID:** NCT01480583
- **Lead sponsor:** Angiochem Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-10
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2016-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01480583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01480583, "GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01480583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*